Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

H Lundbeck A/S receives European marketing authorization for Brintellix for the treatment of adults with Major Depressive Episodes


Friday, 27 Dec 2013 10:22am EST 

H Lundbeck A/S:Says the European Commission granted marketing authorization for Brintellix (vortioxetine) for the treatment of adults with Major Depressive Episodes, commonly referred to as depression.Says the approval will be applicable to all 28 European Union member states plus Iceland, Liechtenstein and Norway.Says subject to the completion of pricing and reimbursement discussions, Lundbeck expects to launch Brintellix in its first markets in H2 2014. 

Company Quote

126.6
-0.9 -0.71%
25 Jul 2014